H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $60 from $63 and keeps a Buy rating on the shares. Arcturus on Thursday announced that interim ...
Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the shares. The firm said its 4Q24 earnings report had ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) missed earnings with its latest annual results, disappointing overly-optimistic forecasters. Unfortunately, Arcturus Therapeutics Holdings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback